Huisheng Biopharma’s self-developed GLP-1R/GCGR dual-target innovative drug P052 injection receives IND approval
September 9, 2025
Source: drugdu
83
According to AI Express of the National Business Daily, on September 9, Sihuan Pharmaceutical announced that its non-wholly owned subsidiary Huisheng Biopharma independently developed an innovative dual-target agonist drug for the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR).The new drug clinical trial application (IND) for P052 injection has been granted implicit approval by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the treatment of type 2 diabetes, overweight or obesity.
https://finance.eastmoney.com/a/202509093508167161.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
